OCTANATE 100 UI/ml, poudre et solvant pour solution injectable ( DrugBank: Octanate )


1 disease
IDDisease name (Link within this page)Number of trials
288Autoimmune acquired coagulation factor deficiency1

288. Autoimmune acquired coagulation factor deficiency


Clinical trials : 205 Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-004435-22-FR
(EUCTR)
01/09/200727/03/2007Incidence of inhibitors in previously untreated patient with severe haemophilia A treated with Octanate (Phase III) - Etude AVI 4-03Incidence of inhibitors in previously untreated patient with severe haemophilia A treated with Octanate (Phase III) - Etude AVI 4-03 Hémophilie A sévère
MedDRA version: 9.1;Level: LLT;Classification code 10018937;Term: Haemophilia A
MedDRA version: 9.1;Classification code 10060612;Term: Hemophilia A
MedDRA version: 9.1;Level: PT;Classification code 10016080;Term: Factor VIII deficiency
MedDRA version: 9.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders
Trade Name: OCTANATE 50 UI/ml, poudre et solvant pour solution injectable
Trade Name: OCTANATE 100 UI/ml, poudre et solvant pour solution injectable
OCTAPHARMA AGNULLNot RecruitingFemale: yes
Male: yes
35Phase 3Czech Republic;France